In 48 new diagnosed epileptic patients, affected by partial simple or complex seizures with or without secondary generalization, GVG was administered as unique drug at a mean dose of 29 mg/kg/day. Minimum follow-up was 3 months, maximum 12 months. In about 80% of the patients a disappearance or a reduction ≥50% of the seizure frequency was obtained, without significant differences between cryptogenic and symptomatic etiology, thoughout the whole period of observation. Side effects, mainly body weight increment, were usually mild and transitory.
|Translated title of the contribution||Vigabatrin monotherapy in partial epilepsy: Preliminary results of a open collaborative study|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1994|
ASJC Scopus subject areas
- Clinical Neurology